



cancers



an Open Access Journal by MDPI

Estrogen Receptor-Positive (ER+) Breast Cancers

Guest Editors:

Prof. Dr. Christos Papadimitriou

Second Department of Surgery,
Aretaieion Hospital, Medical
School, National and
Kapodistrian University of
Athens, 11528 Athens, Greece

Prof. Dr. Dimitrios Mavroudis

Head, Department of Medical
Oncology, University of Crete
Medical School, Heraklion,
Greece

Prof. Dr. Nicholas Pavlidis

Emeritus Professor, University of
Ioannina, Greece and Dean,
European School of Oncology
College, Greece

Message from the Guest Editors


This Special Issue focuses on the biology of ER and the implications of ESR1 mutations in HR+ breast cancer, the role of neoadjuvant therapy, the use of multigene assays to select treatment for early disease, the optimal management of premenopausal patients with ER+ breast cancer, the role of extended adjuvant endocrine therapy, the molecular mechanisms mediating endocrine resistance emphasizing the prominent role of the PI3K/Akt/mTOR and CDK4/6/retinoblastoma protein pathways in cancer cell growth and survival, the molecularly targeted agents to overcome or delay endocrine resistance, and potential predictive biomarkers for accurate patient stratification.

Deadline for manuscript
submissions:
closed (31 March 2021)



mdpi.com/si/50560

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)